CA2391416A1 - Combinaisons oncolytiques destinees au traitement du cancer - Google Patents

Combinaisons oncolytiques destinees au traitement du cancer Download PDF

Info

Publication number
CA2391416A1
CA2391416A1 CA002391416A CA2391416A CA2391416A1 CA 2391416 A1 CA2391416 A1 CA 2391416A1 CA 002391416 A CA002391416 A CA 002391416A CA 2391416 A CA2391416 A CA 2391416A CA 2391416 A1 CA2391416 A1 CA 2391416A1
Authority
CA
Canada
Prior art keywords
ethyl
propoxy
fluorophenyl
hydroxyphenoxy
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002391416A
Other languages
English (en)
Inventor
Jerome Herbert Fleisch
William Thomas Mcmillen
Beverly Ann Teicher
Jason Scott Sawyer
Douglas Wade Beight
Edward C. R. Smith
Roger Stuart Benjamin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2391416A1 publication Critical patent/CA2391416A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

Selon l'invention, des antagonistes de leucotriène (LTB¿4?) augmentent l'efficacité des agents anti-cancéreux 2',2'-difluoronucléosides.
CA002391416A 1999-11-11 2000-11-09 Combinaisons oncolytiques destinees au traitement du cancer Abandoned CA2391416A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16478699P 1999-11-11 1999-11-11
US60/164,786 1999-11-11
PCT/US2000/031039 WO2001034137A2 (fr) 1999-11-11 2000-11-09 Combinaisons oncolytiques destinees au traitement du cancer

Publications (1)

Publication Number Publication Date
CA2391416A1 true CA2391416A1 (fr) 2001-05-17

Family

ID=22596085

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002391416A Abandoned CA2391416A1 (fr) 1999-11-11 2000-11-09 Combinaisons oncolytiques destinees au traitement du cancer

Country Status (22)

Country Link
EP (1) EP1231938A2 (fr)
JP (1) JP2003513916A (fr)
KR (1) KR20020069512A (fr)
CN (1) CN1390139A (fr)
AR (1) AR032432A1 (fr)
AU (1) AU778829B2 (fr)
BR (1) BR0015490A (fr)
CA (1) CA2391416A1 (fr)
CZ (1) CZ20021551A3 (fr)
EA (1) EA200200545A1 (fr)
HK (1) HK1050132A1 (fr)
HU (1) HUP0204449A3 (fr)
IL (1) IL148579A0 (fr)
MX (1) MXPA02004733A (fr)
NO (1) NO20022245L (fr)
NZ (1) NZ517667A (fr)
PE (1) PE20010701A1 (fr)
PL (1) PL355172A1 (fr)
SK (1) SK6492002A3 (fr)
TR (1) TR200201245T2 (fr)
WO (1) WO2001034137A2 (fr)
ZA (1) ZA200202822B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797723B1 (en) 1999-11-11 2004-09-28 Eli Lilly And Company Heterocycle substituted diphenyl leukotriene antagonists
WO2001034197A2 (fr) * 1999-11-11 2001-05-17 Eli Lilly And Company Combinaisons oncolytiques aux fins du traitement de cancer
AU1916601A (en) * 1999-11-11 2001-06-06 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
JP2001247459A (ja) 2000-03-03 2001-09-11 Oakland Uniservices Ltd 癌の組み合わせ療法
JP2003532675A (ja) * 2000-05-09 2003-11-05 クレイトン ユニバーシティ 癌細胞の増殖を阻害しそのアポトーシスを誘導する方法
EP1311262A4 (fr) 2000-07-28 2005-06-01 Cancer Rec Tech Ltd Traitement combine contre le cancer
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
ATE515494T1 (de) 2004-05-05 2011-07-15 High Point Pharmaceuticals Llc Neue verbindungen, deren herstellung und verwendung
ES2352085T3 (es) 2004-05-05 2011-02-15 High Point Pharmaceuticals, Llc Nuevos compuestos, su preparación y uso.
CN1302782C (zh) * 2005-01-17 2007-03-07 北京京卫燕康药物研究所有限公司 盐酸吉西他滨溶液型注射剂
US7943669B2 (en) 2005-06-30 2011-05-17 High Point Pharmaceuticals, Llc Phenoxy acetic acids as PPAR delta activators
EP1979311B1 (fr) 2005-12-22 2012-06-13 High Point Pharmaceuticals, LLC Acides phénoxyacétiques en tant qu'activateurs ppar delta
CA2645719A1 (fr) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Nouveaux composes, leur preparation et utilisation
EP2080751A4 (fr) 2006-10-12 2011-06-22 Inst Med Molecular Design Inc Dérivé d'acide carboxylique
US8633245B2 (en) 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
WO2014060381A1 (fr) 2012-10-18 2014-04-24 Bayer Cropscience Ag Composés hétérocycliques pour la lutte contre les nuisibles
WO2014067962A1 (fr) 2012-10-31 2014-05-08 Bayer Cropscience Ag Nouveaux composés hétérocycliques utilisés comme agents de lutte contre les nuisibles
CN103319466B (zh) * 2013-07-04 2016-03-16 郑州大学 含香豆素母核的1,2,3-三唑-氨基二硫代甲酸酯化合物、制备方法及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation

Also Published As

Publication number Publication date
SK6492002A3 (en) 2003-09-11
NO20022245L (no) 2002-07-09
NZ517667A (en) 2004-05-28
AR032432A1 (es) 2003-11-12
WO2001034137A2 (fr) 2001-05-17
NO20022245D0 (no) 2002-05-10
HK1050132A1 (zh) 2003-06-13
MXPA02004733A (es) 2002-08-30
BR0015490A (pt) 2002-07-09
JP2003513916A (ja) 2003-04-15
CZ20021551A3 (cs) 2003-02-12
ZA200202822B (en) 2003-09-23
HUP0204449A2 (hu) 2003-04-28
EP1231938A2 (fr) 2002-08-21
PE20010701A1 (es) 2001-07-07
IL148579A0 (en) 2002-09-12
TR200201245T2 (tr) 2004-08-23
CN1390139A (zh) 2003-01-08
AU778829B2 (en) 2004-12-23
HUP0204449A3 (en) 2006-02-28
AU1599001A (en) 2001-06-06
WO2001034137A3 (fr) 2002-02-14
PL355172A1 (en) 2004-04-05
EA200200545A1 (ru) 2002-12-26
KR20020069512A (ko) 2002-09-04

Similar Documents

Publication Publication Date Title
CA2391416A1 (fr) Combinaisons oncolytiques destinees au traitement du cancer
JP6364028B2 (ja) 選択的エストロゲン受容体ディグレーダーとしてのベンゾチオフェン誘導体およびその組成物
TW446704B (en) Naphtho[2,3-B]heteroar-4-yl derivatives for treating metabolic disorders related to insulin resistance or hyperglycemia
ES2397664T3 (es) Derivados de glucopiranósilo que contienen tienilo como antidiabéticos
JP2003531194A (ja) プロスタグランジンｅ阻害薬としてフェニルおよびビアリール誘導体を用いる治療方法および該方法に有用な化合物
CN106188045A (zh) 作为wnt信号传导抑制剂的化合物、组合物及其应用
US8338481B2 (en) Alkoxyalkyl S-prenylthiosalicylates for treatment of cancer
Giles et al. Synthesis pharmacological evaluation and docking studies of pyrimidine derivatives
CA2390789A1 (fr) Combinaisons oncolytiques pour traitement des cancers
AU2014364732A1 (en) Substituted piperidinyl-tetrahydroquinolines and their use as alpha-2C adrenoreceptor antagonists
JP2003509419A (ja) カルボン酸類およびアシルスルホンアミド類、そのような化合物を含む組成物、ならびに治療方法
US8822519B2 (en) Compound with agitation effect on peroxisome proliferator-activated receptor process for its preparation and use thereof
WO2005079803A1 (fr) Composes pour traitement des maladies cardio-vasculaires
US20170128434A1 (en) Novel estrogen receptor ligands
WO2001034198A2 (fr) Combinaisons oncolytiques pour traitement des cancers
WO2001034197A2 (fr) Combinaisons oncolytiques aux fins du traitement de cancer
ES2207108T3 (es) Derivados de acido aril carboxilico y tetrazol con un grupo de carbamoiloxi.
WO2019031470A1 (fr) Nouveau composé à base d'amide, et inhibiteur de pin1, agent thérapeutique contre les maladies inflammatoires ainsi qu'agent thérapeutique contre le cancer mettant en œuvre celui-ci
KR20100016512A (ko) 심근경색증 치료를 위한 철 킬레이터의 용도
KR101360579B1 (ko) 신규 페닐초산 유도체
JP2023511679A (ja) 二置換アダマンチル誘導体、その薬学的に許容される塩、およびこれを有効成分として含む癌の増殖抑制用薬学的組成物
US10183908B2 (en) Compositions for the treatment of kidney and/or liver disease
GB2397817A (en) Coumarin derivative
CA2391230A1 (fr) Diphenyles a substitution heterocycle utilises comme antagonistes de leucotriene
JP2023175716A (ja) リン酸塩誘導体およびその用途

Legal Events

Date Code Title Description
FZDE Discontinued